Answers are grounded in this paper and cite their sources.
Background Immune checkpoint inhibitors (ICIs) are increasingly used in metastatic breast cancer (mBC), yet real-world data on immune-related adverse events (irAEs) is limited. Patients and Methods We conducted a retrospective cohort study across four NCI-designated cancer centers. Adults with mBC treated with ICIs between 2014–2024 were included. irAEs were defined by provider attribution or treatment with high-dose corticosteroid and exclusion of other clear cause. Predictors of irAE were assessed using multivariable logistic regression. Overall survival (OS) was evaluated using a 12-week landmark analysis. Results Among 522 patients (mean age 55.4), most received pembrolizumab (83.9%) and ICI in combination (82.7%). Over a median follow-up of 17.5 months, 42.5% experienced ≥1 irAE and 13.2% had severe (grade 3-4) events. Lower odds of irAE were observed for Black race (OR 0.43; p=0.028), low albumin (OR 0.50; p=0.007), and low hemoglobin (Hgb) (OR 0.60; p=0.009), while higher odds were associated with age 46-55 (OR 1.76, p=0.035), CDK4/6 inhibitor use (OR 1.82; p=0.030) and ≥4 ICI cycles (OR 1.70; p=0.007). Among 332 patients included in the landmark analysis, grade 1–3 irAEs were associated with superior OS compared with no irAE, whereas grade 4 irAEs were associated with inferior OS (log-rank p<0.0001). Conclusion In this multi-institutional real-world cohort of mBC patients treated with ICIs, irAEs were more frequent than reported in breast cancer clinical trials. ICI duration and CDK4/6 inhibitor use increased irAE risk, while baseline albumin influenced survival. Mild to moderate irAEs were associated with improved outcomes, but severe irAEs portended worse survival. These findings support risk-stratified ICI use in mBC. Microabstract Purpose: To characterize the incidence, predictors, and survival impact of immune-related adverse events (irAEs) in patients with metastatic breast cancer (mBC) treated with immune checkpoint inhibitors (ICIs). Patients and Methods: We conducted a retrospective cohort study of 522 adults with mBC treated with ICIs. irAEs were identified by provider attribution or corticosteroid use. Predictors were evaluated using multivariable logistic regression, and overall survival (OS) was assessed using a 12-week landmark analysis. Results: Over a median follow-up of 17.5 months, 42.5% developed ≥1 irAE and 13.2% experienced grade 3–4 events. Increased irAE risk was associated with age 46–55, CDK4/6 inhibitor use, and ≥4 ICI cycles, while Black race, low albumin, and low hemoglobin were protective. Grade 1–3 irAEs were associated with improved OS, whereas grade 4 irAEs were associated with worse OS. Conclusion: irAEs are common and clinically meaningful in mBC, supporting risk-stratified ICI use.
No takes yet. Share an insight, caveat, or question.
Baclig et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: